What is the success rate of stem cell therapy for Parkinson's Disease?
No general success rate exists. For the exact product and protocol, examine blinded motor and non-motor outcomes, medication state, comparator, graft imaging only as supportive evidence, adverse events and complete follow-up. A biomarker or dopamine signal is not functional independence.
What the evidence shows for Parkinson's Disease
Cell-replacement programmes remain specialised clinical research and must establish identity, purity, dose, surgical delivery, tumour risk, graft survival and clinically meaningful function. Laboratory generation of dopamine-producing neurons supports a research hypothesis, not a commercial efficacy claim. The NINDS stem-cell research overview describes this work, while the FDA patient page states that regenerative medicine therapies are not approved in the United States for Parkinson's disease.
Am I a candidate? → · Parkinson's Disease: full overview → · Parkinson's Disease cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Parkinson's Disease: cell-therapy evidence and registered trials
- How much does stem cell therapy for Parkinson's Disease cost? (2026)
- Parkinson's Disease stem cell therapy — your questions answered (2026)
- Parkinson's Disease: cell-therapy evidence by therapy class
- MSC vs exosomes for Parkinson's Disease: what the registries show